Increased propensity for calcium phosphate kidney stones with topiramate use. - Wikidata - awgldk - TriplyDB

Increased propensity for calcium phosphate kidney stones with topiramate use.

Increased propensity for calcium phosphate kidney stones with topiramate use.

http://www.wikidata.org/entity/Q36945018

about

Review of topiramate for the treatment of epilepsy in elderly patients.Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review.Nephrolithiasis in topiramate users.Anticonvulsant-induced rickets and nephrocalcinosis.Prevalence and spot urine risk factors for renal stones in children taking topiramate.Zonisamide in the treatment of epilepsy.Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels.The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension.The effect of antiepileptic drugs on the kidney function and structure.The Use of Antiepileptics in Migraine Prophylaxis.Topiramate-induced nephrolithiasis.Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly.Incidence of kidney stones with topiramate treatment in pediatric patients.

P2860

Q33819386-9BF6DC39-7A5C-4ACF-B3CB-33EC869E0F71 Q33887963-2C2A5DDD-1F16-4F95-8533-9D5AC7C4E77E Q33919910-A3AD27E5-C238-435F-9801-2A0108815A6B Q35792495-433793C6-7ED8-4B0F-BFF1-31A6236873B0 Q36816967-6D03D9D9-39F5-4632-9F5F-14FE36FE5B49 Q37650321-437FDA69-11D3-4C81-B120-02FD550B3A5C Q37779809-28DA9001-596B-4499-9159-0ED6410A7169 Q37994720-7658595F-4264-45D6-8D08-035F78629413 Q38285279-83383E59-E0A6-478A-A96B-DB7AC4DBAA85 Q38687924-63176822-61E5-4A8A-8FAE-30EF1B25A96B Q38758229-DCF51D2C-2095-4183-A541-42775E7A7157 Q41134916-A03FEA94-3C35-485C-A8CB-5C7540D3174D Q49629769-C972FCA8-1680-42EC-BB92-D82E4E226CC7 Q51004475-22AEF627-697C-4A95-9246-35AEC2CD1A83 Q51419801-0482A2D1-447E-45C6-AD96-D3715D88DFE8

P2860

Increased propensity for calcium phosphate kidney stones with topiramate use.

http://www.wikidata.org/entity/Q36945018

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Increased propensity for calcium phosphate kidney stones with topiramate use.

@en

type

label

Increased propensity for calcium phosphate kidney stones with topiramate use.

@en

prefLabel

Increased propensity for calcium phosphate kidney stones with topiramate use.

@en

P1433

Q36945018-97C75D3C-37E3-4922-B3EA-E90E064268EB

P1476

Q36945018-0B45E57F-FF46-46A1-A879-96E5736287F9

P2093

Q36945018-3A39E3B8-CF82-4812-AF39-632A309A88B6

Q36945018-6BC03007-FCFC-42B9-8279-B0C826EDB4A0

Q36945018-8E1CFA71-EC08-41AC-AFB9-08FD464B8197

P2860

Q36945018-00E0FB9D-E5B8-4CC1-96C2-784FFF3DFA2D

Q36945018-038AAB3A-5E16-4C8E-B38C-605C3541BA2B

Q36945018-116A540B-AE6B-4AAA-86D4-B70C036C2E38

Q36945018-21580984-0BB1-46F7-BC88-4B120A745144

Q36945018-27D04EE4-720A-494F-AB12-CD03FD4618B0

Q36945018-29818E70-5C30-4AE4-AA94-FEA8BCFDEC64

Q36945018-299B4E4A-6FF7-414D-AB16-7CDB92A592B2

Q36945018-3C3B3E6B-50FE-4C12-AC52-683C750E75EA

Q36945018-3C408064-AFC2-49B4-9700-E19521069696

Q36945018-43DEDF22-0551-498B-9BFC-A99545147BD6

P304

Q36945018-26AB4248-D3F0-4907-9B7B-2636A9CBFDB8

P31

Q36945018-1F5895DF-F488-4A62-A5B5-96E4E0DCC764

P356

Q36945018-E425F1CF-DF02-4707-9BF7-94F65234A896

P407

Q36945018-FFF6A162-0B3C-4A09-BE1A-11036E7A6C96

P433

Q36945018-CA6B9070-3F82-480E-9E92-1F3AE16C9534

P478

Q36945018-613C1EA0-1B2A-4B70-BA69-746865A82CCE

P577

Q36945018-70F0FB00-6761-47B0-946A-DEF617880EEA

P698

Q36945018-23B112A4-804D-46BB-8318-1E222C9EE819

P356

14740338.6.5.547

P1433

Expert Opinion on Drug Safety

P1476

Increased propensity for calcium phosphate kidney stones with topiramate use.

@en

P2093

Damaris Vega

http://www.w3.org/2001/XMLSchema#string

Khashayar Sakhaee

http://www.w3.org/2001/XMLSchema#string

Naim M Maalouf

http://www.w3.org/2001/XMLSchema#string

P2860

Kidney stone disease.

Carbonic anhydrase isozymes IV and II in urinary membranes from carbonic anhydrase II-deficient patients

Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification

The role of carbonic anhydrases in renal physiology

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group.

Localization of membrane-associated carbonic anhydrase type IV in kidney epithelial cells.

Influence of topiramate in the regulation of energy balance.

PRODUCTION, EXCRETION, AND NET BALANCE OF FIXED ACID IN PATIENTS WITH RENAL ACIDOSIS

P304

547-557

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.6.5.547

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17877442

http://www.w3.org/2001/XMLSchema#string